Donald Trump has been upending the world order since his return to the White House in January. In the second instalment of a ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

through its enhanced comprehensive outpatient HIV/AIDS treatment coverage. This enhancement aligns with President Ferdinand R. Marcos, Jr.’s directive to prioritize early diagnosis and treatment, ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Boston Public Health Commission (BPHC) announced the launch of a new campaign, called Let’s Talk HIV Boston, aimed at increasing awareness and reducing HIV-related stigma with a focus on educating the ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...

Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...